IMPORTANT INFORMATION

This website is no longer being updated.

NHS Rotherham Clinical Commissioning Group has, from 1 July 2022, been replaced by the new NHS South Yorkshire Integrated Care Board (ICB). The ICB is now responsible for commissioning and funding of health and care services in the local area. Please go to our new website www.southyorkshire.icb.nhs.uk for information about the work of NHS South Yorkshire ICB.

For local health information visit Your Health Rotherham

To view an archive of this website, please click here

Thank you.

branch graphic

FOI Disclosure Log

Use the form below to search for FAQs containing specific words

Search for:
CCG 1346 CCG Contact Information and Patient Care

 Request 1

What criteria does the CCG use to select which inhalers should be prescribed for Asthma and COPD?

Response 1

The CCG uses clinical trials to check efficacy, cost-effectiveness and ensures that the inhalers chosen will meet the requirements of patients.  Secondary care, using their expertise will have input and will check that the guidelines and inhalers chosen are suitable for patients before ratification.

Request 2

How does the CCG compare the cost-effectiveness , efficacy, safety and patient usability of different inhalers when selecting which COPD and Asthma inhalers should be included on its local guidance?

Response 2

Cost-effectiveness, efficacy, safety are compared using clinical trial data and drug tariff prices. Patient usability is assessed using clinical experience.

Request 3

Over the past three years, has the CCG introduced a planned programme of care which resulted in the medicines optimisation team, contractors or GP practices proactively reviewing patients and aligning their COPD and/or Asthma inhalers to alternative options.

Response 3

Over the past three years the CCG has reviewed patients and aligned COPD and/or Asthma inhalers to more cost effective alternatives.

Request 4

Please list the alternative asthma and COPD inhalers that were introduced by the CCGs medicines optimisation team, contractors or GP practices during any planned programme of care that proactively reviewed the use of asthma and/or COPD inhalers over the past 3 years .

Response 4

Tiotropium HandiHaler to Braltus

Patients initiated on Fluticasone/Salmeterol combination MDI started on Sirdupla

Request 5

Over the past three years, has the CCG used a QIPP scheme to introduce a planned programme of care which resulted in the medicines optimisation team, contractors or GP practices proactively reviewing patients and aligning their COPD and/or Asthma inhalers to alternative options?

Response 5

Tiotropium HandiHaler to Braltus

Patients initiated on Fluticasone/Salmeterol combination MDI started on Sirdupla

Request 6

Please list the alternative asthma and COPD inhalers that were introduced by the CCGs medicines optimisation team, contractors or GP practices when using a QIPP scheme to introduce a planned programme of care that proactively reviewed the use of asthma and/ or COPD inhalers over the past 3 years?

Response 6

Tiotropium Handihaler to Braltus

Patients initiated on Fluticasone/Salmeterol combination MDI started on Sirdupla

Request 7

I would also like to make a request for the full name, contact number and contact email for the following roles listed below within your CCG;

Chief Officer

Chief Financial Officer

Medicines Management Lead

Response 7

Roles:

Chief Officer – Mr. Chris Edwards, chris.edwards@rotherhamccg.nhs.uk

Chief Finance Officer – Mrs. Wendy Allott , wendy.allott@rotherhamccg.nhs.uk

Medicines Management Lead – Mr. Stuart Lakin, stuart.lakin@rotherhamccg.nhs.uk

Contact number 01709 302000